Seronegative Myasthenia Gravis

 

 Buy Article Permissions and Reprints

Some myasthenia gravis (MG) patients do not have detectable acetylcholine receptor (AChR) antibodies and have been termed “seronegative” (SNMG) in many previous studies. A high proportion of patients with purely ocular symptoms, ocular MG, are seronegative; this may be because the sensitivity of the assay is insufficient to detect low levels of circulating AChR antibodies and because of intrinsic differences in the ocular muscles that make them more susceptible to circulating factors. Seronegative generalized myasthenia is proving to be heterogeneous both clinically and immunologically. Plasma from SNMG patients often contains a factor, probably an immunoglobulin M antibody, that alters AChR function in in vitro assays, but its target is not yet clear. A variable proportion of SNMG patients have antibodies to the muscle-specific tyrosine kinase (MuSK). These antibodies are directed against the extracellular domain of MuSK and inhibit agrin-induced AChR clustering in muscle myotubes. Although the role of these antibodies in causing myasthenic symptoms in vivo has not been elucidated, MuSK antibodies appear to define a group of patients who are often female with bulbar weakness, contrasting with MuSK antibody-negative SNMG patients who are more likely to have generalized weakness. MuSK antibody-positive patients may also differ in the distribution of their electrophysiological abnormalities and their responses to treatments.

REFERENCES

• 1 Lindstrom J M, Seybold M E, Lennon V A, Whittingham S, Duane D D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.  Neurology. 1976;  26 1054-1059
  CrossrefPubMedGoogle Scholar
• 2 Lefvert A K, Bergstrom K. Acetylcholine receptor antibody in myasthenia gravis: purification and characterization.  Scand J Immunol. 1978;  8 525-533
  PubMedGoogle Scholar
• 3 Sanders D B, Andrews I, Howard J F, Massey J M. Seronegative myasthenia gravis.  Neurology. 1978;  28 266-272
  PubMedGoogle Scholar
• 4 Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.  J Neurol Neurosurg Psychiatry. 1985;  48 1246-1252
  CrossrefPubMedGoogle Scholar
• 5 Somner N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.  Doc Ophthalmol. 1993;  84 309-333
  CrossrefPubMedGoogle Scholar
• 6 Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis.  Clin Neurophysiol. 2000;  111 1203-1207
  CrossrefPubMedGoogle Scholar
• 7 Sadeh M, Stern L Z. Observations on the innervation of human extraocular muscles.  J Neurol Sci. 1984;  66 295-305
  CrossrefPubMedGoogle Scholar
• 8 Kaminski H J, Richmonds C R, Kusner L L, Mitsumoto H. Differential susceptibility of the ocular motor system to disease.  Ann N Y Acad Sci. 2002;  956 42-54
  PubMedGoogle Scholar
• 9 Kaminski H J, Kusner L L, Block C H. Expression of acetylcholine receptor isoforms at extraocular muscle endplates.  Invest Ophthalmol Vis Sci. 1996;  37 345-351
  PubMedGoogle Scholar
• 10 Horton R M, Conti-Tronconi B M, Manfredi A A. ACh receptor in ocular MG.  Neurology. 1994;  44 778-779
  PubMedGoogle Scholar
• 11 MacLennan C, Beeson D, Buijs A M et al.. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis.  Ann Neurol. 1997;  41 423-431
  CrossrefPubMedGoogle Scholar
• 12 Vincent A, Newland C, Brueton L et al.. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen.  Lancet. 1995;  346 24-25
  CrossrefPubMedGoogle Scholar
• 13 Senanayake N, Roman G C. Disorders of neuromuscular transmission due to natural environmental toxins.  J Neurol Sci. 1992;  107 1-13
  CrossrefPubMedGoogle Scholar
• 14 Fischer M D, Gorospe J R, Felder E et al.. Expression profiling reveals metabolic and structural components of extraocular muscles.  Physiol Genomics. 2002;  9 71-84
  PubMedGoogle Scholar
• 15 Khanna S, Richmonds C R, Kaminski H J, Porter J D. Molecular organization of the extraocular muscle neuromuscular junction: partial conservation of and divergence from the skeletal muscle prototype.  Invest Ophthalmol Vis Sci. 2003;  44 1918-1926
  CrossrefPubMedGoogle Scholar
• 16 Nemoto Y, Kuwabara S, Kawaguchi N, Vincent A, Hattori T. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis.  Muscle Nerve. , Submitted for publication
  PubMedGoogle Scholar
• 17 Evoli A, Tonali P A, Padua L et al.. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.  Brain. 2003;  126 2304-2311
  CrossrefPubMedGoogle Scholar
• 18 Vincent A, Li Z, Hart A et al.. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function.  Ann N Y Acad Sci. 1993;  681 529-538
  PubMedGoogle Scholar
• 19 Drachman D B, de Silva S, Ramsay D, Pestronk A. Humoral pathogenesis of myasthenia gravis.  Ann N Y Acad Sci. 1987;  505 90-105
  PubMedGoogle Scholar
• 20 Tsujihata M, Yoshimura T, Satoh A et al.. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis.  Neurology. 1989;  39 1359-1363
  PubMedGoogle Scholar
• 21 Verma P K, Oger J J. Seronegative generalized myasthenia gravis: low frequency of thymic pathology.  Neurology. 1992;  42 586-589
  PubMedGoogle Scholar
• 22 Willcox N, Schluep M, Ritter M A, Newsom-Davis J. The thymus in seronegative myasthenia gravis patients.  J Neurol. 1991;  238 256-261
  PubMedGoogle Scholar
• 23 Mier A K, Havard C W. Diaphragmatic myasthenia in mother and child.  Postgrad Med J. 1985;  61 725-727
  PubMedGoogle Scholar
• 24 Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.  Lancet. 1986;  1 116-119
  PubMedGoogle Scholar
• 25 Evoli A, Batocchi A P, Lo Monaco M et al.. Clinical heterogeneity of seronegative myasthenia gravis.  Neuromuscul Disord. 1996;  6 155-161
  PubMedGoogle Scholar
• 26 Burges J, Vincent A, Molenaar P C et al.. Passive transfer of seronegative myasthenia gravis to mice.  Muscle Nerve. 1994;  17 1393-1400
  PubMedGoogle Scholar
• 27 Blaes F, Beeson D, Plested P et al.. IgG from “seronegative” myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor.  Ann Neurol. 2000;  47 504-510
  CrossrefPubMedGoogle Scholar
• 28 Poea S, Guyon T, Bidault J et al.. Modulation of acetylcholine receptor expression in seronegative myasthenia gravis.  Ann Neurol. 2000;  48 696-705
  CrossrefPubMedGoogle Scholar
• 29 Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction.  Muscle Nerve. 2002;  25 4-16
  PubMedGoogle Scholar
• 30 Hoch W, McConville J, Helms S et al.. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.  Nat Med. 2001;  7 365-368
  CrossrefPubMedGoogle Scholar
• 31 Scuderi F, Marino M, Colonna L et al.. Anti-p110 autoantibodies identify a subtype of “seronegative” myasthenia gravis with prominent oculobulbar involvement.  Lab Invest. 2002;  82 1139-1146
  PubMedGoogle Scholar
• 32 McConville J, Farrugia M E, Beeson D et al.. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.  Ann Neurol. 2004;  55 580-584
  CrossrefPubMedGoogle Scholar
• 33 Plested C P, Tang T, Spreadbury I et al.. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.  Neurology. 2002;  59 1682-1688
  PubMedGoogle Scholar
• 34 Yamamoto T, Vincent A, Ciulla T A et al.. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM.  Ann Neurol. 1991;  30 550-557
  CrossrefPubMedGoogle Scholar
• 35 Spreadbury I, Kishore U, Beeson D, Vincent A. A non-IgG factor in seronegative myasthenia gravis causes inhibition of muscle acetylcholine receptors correlated with desensitisation. Submitted for publication
  Google Scholar
• 36 Sanders D B, El-Salem K, Massey J M et al.. Clinical aspects of MuSK antibody positive seronegative MG.  Neurology. 2003;  60 1978-1980
  CrossrefPubMedGoogle Scholar
• 37 Newsom-Davis J, McConville J, Kennett R, Anslow P, Hoch W, Vincent A. Anti-MuSK antibodies in seronegative myasthenia gravis: a cause of denervation.  J Neurol Neurosurg Psychiatry. 2001;  71 421
  PubMedGoogle Scholar
• 38 Zhou S L, McConville J, Chaudhry V et al.. Clinical comparison of MuSK antibody positive and negative myasthenic patients.  Muscle Nerve. , In press
  PubMedGoogle Scholar
• 39 Burke G, Cossins J, Maxwell S et al.. Rapsyn mutations in hereditary myasthenia. Distinct early- and late- onset phenotypes.  Neurology. 2003;  61 826-828
  CrossrefPubMedGoogle Scholar
• 40 Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.  Lancet Neurol. 2003;  2 99-106
  CrossrefPubMedGoogle Scholar

Angela VincentM.D. 

Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine

John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom